New knowledge on molecular mechanisms behind breast cancer

September 25, 2013

Researchers at University of Copenhagen have gained more insight into the molecular mechanisms of importance for, for example, cancer cell growth and metastasis. The research objective is improved and more targeted drugs. The findings have just been published in the scientific journal Molecular Cell.

Researchers are constantly trying to learn more about the body's advanced communication processes. Receptors serve as a kind of switchboard in the cell, which connects specific signaling proteins to specific cellular functions. Using state-of-the-art technology, researchers at University of Copenhagen have studied a special of major importance for health and disease. The findings have been published in a new scientific paper:

"We have pinpointed the binding site that can cause increased spreading of cells and thus the development of metastases," says professor Jesper Velgaard Olsen.

"In simple terms, we have mapped the on the receptor that turns two important biological processes on and off, respectively. We have, in other words, pinpointed the binding site that can cause increased spreading of and thus the development of metastases.

We have studied two cellular signaling proteins with each their widely different biological influence on the so-called FGFR2b receptor. One of the proteins is involved in cell division, whereas the other controls cell movement. Both processes are important for a healthy cell, but if they spin out of control it may have serious implications, e.g. in the form of and development of metastases,"says Professor and protein researcher Jesper Velgaard Olsen, The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen.

The findings have just been published in the scientific journal Molecular Cell.

The FGFR2b receptor is co-responsible for the optimal development of inner organs at the , in particular lung tissue. A dysfunction in the receptor's signal therefore has serious implications for normal lung tissue function. The receptor has also proved to play an important role in certain types of breast cancer.

Better drugs in the future

The new research is based on human cancer cells and murine tissue but may, in the long run, help improve the customised treatment of, e.g., breast cancer in humans:

"Doctors currently use special biomarkers for diagnosing and treating cancers. The FGFR2b receptor may in the future serve as a new biomarker. The more we know about the body's transmission systems, the better we become at targeting medical treatment. Hopefully, we will in future be able to offer customised treatment based on the individual patient's cellular profile," says Professor Jesper Velgaard Olsen.

The researchers have used state-of-the-art technology within at The Novo Nordisk Foundation Center for Protein Research:

"Using advanced mass spectrometry allows us to study cellular proteins in such detail that was previously only possible within the field of genetics. It was previously a huge challenge to analyze proteins – but today we can study thousands of proteins in a very short time", says Professor Jesper Velgaard Olsen.

Explore further: New protein knowledge offers hope for better cancer treatment

Related Stories

New protein knowledge offers hope for better cancer treatment

September 19, 2013
When the pharmaceutical industry develops new medicines – for example for cancer treatment – it is important to have detailed knowledge of the body's molecular response to the medicine.

Researchers identify key protein's role in cancer development

August 30, 2013
Researchers at the University of Cincinnati (UC) have identified a key protein as the first dual-function co-regulator of an estrogen receptor that plays a crucial role in cancer development, opening the way to improved therapeutic ...

Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents

July 24, 2013
Small proteins called peptides that consist of 10 to 50 amino acids are being studied as cancer vaccines and as possibly safer, more effective and less costly alternatives to the monoclonal-antibody-based drugs and small-molecule ...

Alternative target for breast cancer drugs

July 19, 2013
Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today ...

New approach in the treatment of breast cancer

August 8, 2013
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team involving the Clinical ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.